智通财经APP讯，心通医疗-B(02160)公布，该集团预期2025年上半年取得净亏损不高于人民币1000万元，同比减少不低于83%。
公告称，净亏损减少主要是由于：VitaFlow Liberty®经导管主动脉瓣膜及可回收输送系统已在海外20余个国家╱地区实现销售，来自海外的收入同比增长两倍以上;AnchorMan®左心耳封堵器系统及其导引系统在中国的商业化进展稳步推进，并于报告期内获得CE标志并在欧洲实现商业化，共同贡献了收入增量;集团通过持续优化资源配置、积极管控各项费用等措施进一步提升运营效率;及集团的联营公司4C Medical Technologies, Inc完成D轮融资，集团于4C Medical的股权比例下降，获得视作出售部分股权的收益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.